My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protalix BioTherapeutics, Inc. (DE) Common Stock (NY:PLX)

1.820 -0.580 (-24.17%)
Streaming Delayed Price Updated: 12:51 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Protalix BioTherapeutics, Inc. (DE) Common Stock

< Previous 1 2 3 4 Next >
Top stock movements in today's session.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Why Is Protalix BioTherapeutics Stock Falling On Friday?
EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy. 
Via Benzinga
Which stocks are gapping on Friday?
Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Protalix BioTherapeutics Stock Tumbled 28% Today: Why The Latest CHMP Opinion Is Sparking Concerns Among Investors?
Via Stocktwits
Earnings Scheduled For August 14, 2025
 
Via Benzinga
Preview: Protalix BioTherapeutics's Earnings
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free
Via ACCESS Newswire
Protalix BioTherapeutics to Present at Investor Summit Virtual
Via ACCESS Newswire
Protalix Revenue Jumps 16 Percent in Q2
Via The Motley Fool
Earnings Outlook For Protalix BioTherapeutics
 
Via Benzinga
Top movers in Friday's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Keep an eye on the top gainers and losers in Friday's session.
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
The market is filled with gapping stocks in Friday's session.
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Wondering what's happening in today's pre-market session?
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For May 9, 2025
 
Via Benzinga
Uncovering Potential: Protalix BioTherapeutics's Earnings Preview
 
Via Benzinga
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a... 
Via Stocktwits
Topics Stocks
Evaluating PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) using Mark Minervini’s winning stock formula
A fundamental and technical analysis of (NYSEARCA:PLX): PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) may be suited for high growth investing, we'll explore why in this article. 
Via Chartmill
Does PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) show the characteristics of a Minervini super stock?
A fundamental and technical analysis of (NYSEARCA:PLX): Is PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) suited for high growth investing? 
Via Chartmill
iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025
Via ACCESS Newswire
Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond
Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025. 
Via Benzinga
Earnings Scheduled For March 17, 2025
 
Via Benzinga
Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
Earnings Scheduled For November 14, 2024
 
Via Benzinga
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Beats Revenue for Q2 2024
PLX stock results show that Protalix BioTherapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.